Home/ Supplements/ Omega 3/ Clinical EPA/DHA Forte

Clinical EPA/DHA Forte

product on market Softgel Capsule Natural Clinician Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 75% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are omega-3 fatty acids with strong evidence for supporting cardiovascular and cognitive health. Research indicates these components help manage triglyceride levels and reduce systemic inflammation. The overall evidence for these ingredients is robust and well-documented in clinical literature.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Clinical EPA/DHA Forte
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Softgel(s)
Serving Size
30
Servings
Fat/Fatty Acid
Product Type
75%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Calories from Fat
20 {Calories}

Other Ingredients

Gel Capsule with Polymer Enteric Coat
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

DIRECTIONS: Take one gel capsule twice daily on an empty stomach with 4 oz. of pure water. Physicians may adjust dosage upwards.

Formulation Notes

Cholesterol free.

Additional Information

PATENT PENDING CLINICAL GRADE FORMULATION

Metadata

Product Details

UPC / SKU0 36733 00801 3
DSLD Entry Date2013-02-25
Product TypeFat/Fatty Acid
FormSoftgel Capsule
DSLD ID18623
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.